Track market-moving stories before they get noisy

Hsbc Holdings PLC grew its position in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 6.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 127,125 shares of the biotechnology company’s stock after purchasing an additional 7,890 shares during the quarter. Hsbc Holdings PLC owned approximately 0.30% of United Therapeutics worth $68,899,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Geneos Wealth Management Inc. lifted its stake in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in United Therapeutics by 18.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after buying an additional 70 shares in the last quarter. Jump Financial LLC bought a new stake in United Therapeutics during the second quarter valued at about $277,000. Cerity Partners LLC raised its holdings in United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after acquiring an additional 5,600 shares during the period. Finally, Bank of Nova Scotia lifted its position in shares of United Therapeutics by 6.9% in the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 105 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at United Therapeutics In related news, CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $493.46, for a total transaction of $4,687,870.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $160,099,642.78. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Paul Mahon sold 8,300 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $482.03, for a total value of $4,000,849.00. Following the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at $21,774,259.16. This represents a 15.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 384,575 shares of company stock worth $204,028,738 over the last quarter. 8.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades UTHR has been the subject of a number of recent analyst reports. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Royal Bank Of Canada decreased their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Weiss Ratings cut United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Bank of America dropped their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Finally, JPMorgan Chase & Co. increased their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $646.00. Read Our Latest Stock Analysis on United Therapeutics

United Therapeutics Price Performance Shares of UTHR stock opened at $487.61 on Tuesday. The company’s fifty day simple moving average is $524.81 and its two-hundred day simple moving average is $540.05. United Therapeutics Corporation has a 52 week low of $375.61 and a 52 week high of $609.35. The stock has a market cap of $20.91 billion, a P/E ratio of 17.45, a PEG ratio of 2.43 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the business posted $6.41 earnings per share. On average, analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

United Therapeutics Profile (Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

See Also Five stocks we like better than United Therapeutics 3 Under-the-Radar Defense Stocks With Record Backlogs This Korea ETF Has Soared, But the Rally May Not Be Over Why Guidewire’s Post-Earnings Plunge May Not Last Ride-Share Reckoning: Tesla Drives Into Uber’s Lane

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

United Therapeutics Corporation (UTHR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Key Takeaways United Therapeutics' Tyvaso sNDA seeks approval for IPF, with an FDA decision expected in April 2027.TETON studies showed significant FVC gains, reduced clinical worsening and favorable secondary endpoints.Integrated TETON data showed a 111.8 mL FVC benefit, supporting Tyvaso's potential in IPF. United Therapeutics (UTHR - Free Report) recently announced that the FDA has accepted its supplemental new drug application (sNDA) for review, seeking approval for expanded use of its marketed drug, nebulized Tyvaso, in idiopathic pulmonary fibrosis (IPF). A regulatory decision is expected in late April 2027. If approved, the product would be the first FDA-approved inhaled anti-fibrotic treatment for the said indication.

United Therapeutics already markets nebulized Tyvaso for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease. Besides the nebulized formulation, the drug is also approved as a dry powder inhalation (DPI) version for the same indications. The company generates majority of its revenues from the Tyvaso franchise.

IPF is a progressive lung-scarring disease that gradually impairs oxygen transfer, often leading to respiratory failure and death. It primarily affects older adults and may be associated with smoking, genetic factors, environmental exposures and acid reflux. In the United States, at least 100,000 people are estimated to live with IPF, highlighting a significant unmet medical need.

Year to date, shares of United Therapeutics have risen 0.9% compared with the industry’s 0.6% growth.

Image Source: Zacks Investment Research

UTHR’s Tyvaso sNDA for IPF Backed by TETON DataThe sNDA was submitted in June, based on positive top-line data from the TETON program, which consisted of two parallel phase III studies, TETON-1 (conducted in the United States and Canada) and TETON-2 (internationally), designed to evaluate nebulized Tyvaso in patients with IPF. Both studies met their primary endpoints, demonstrating statistically significant improvement in lung function for IPF patients, including a meaningful increase in forced vital capacity (FVC). The studies also reduced the risk of clinical worsening and showed favorable trends across key secondary endpoints.

Integrated analyses of studies reinforced these findings, showing a 111.8 mL FVC benefit and broad secondary endpoint improvements.

In addition to IPF, United Therapeutics is conducting a late-stage TETON PPF study to evaluate the therapy in progressive pulmonary fibrosis (PPF). The company completed patient enrollment in August, with top-line data anticipated in the second half of 2027.

UTHR's Zacks Rank & Stocks to ConsiderUnited Therapeutics currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Precigen (PGEN - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), and AC Immune (ACIU - Free Report) and Aldeyra Therapeutics (ALDX - Free Report) , carrying a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 30 days, estimates for Precigen’s 2026 bottom line have improved from a loss of 2 cents per share to earnings of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents per share. PGEN shares have surged 68% year to date.

Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.

Over the past 30 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents per share. ACIU shares have lost 9.6% year to date.

AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.

Over the past 30 days, loss per share estimates for Aldeyra Therapeutics have narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX shares have plunged 71.1% year to date.

Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.

Corient Private Wealth LP purchased a new stake in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 15,582 shares of the biotechnology company’s stock, valued at approximately $8,443,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in United Therapeutics in the second quarter valued at $2,868,735,000. Wellington Management Group LLP boosted its holdings in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. Jupiter Topco LLC bought a new stake in United Therapeutics in the 2nd quarter valued at $450,140,000. Norges Bank bought a new stake in shares of United Therapeutics in the fourth quarter valued at about $293,418,000. Finally, Avoro Capital Advisors LLC grew its position in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance United Therapeutics stock opened at $515.46 on Monday. The stock has a 50-day moving average price of $530.46 and a two-hundred day moving average price of $539.16. United Therapeutics Corporation has a 12 month low of $303.08 and a 12 month high of $609.35. The company has a market capitalization of $22.11 billion, a PE ratio of 18.44, a P/E/G ratio of 1.75 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the previous year, the company posted $6.41 EPS. The business’s revenue was down 1.9% on a year-over-year basis. As a group, analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year. Insider Activity at United Therapeutics In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,311,581.28. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $547.61, for a total transaction of $5,202,295.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,185,323.93. This represents a 19.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 404,575 shares of company stock valued at $216,652,640. Company insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades A number of equities analysts have commented on UTHR shares. JPMorgan Chase & Co. raised their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Morgan Stanley set a $515.00 target price on United Therapeutics in a research report on Thursday, August 6th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Royal Bank Of Canada reduced their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Finally, Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $646.00.

Check Out Our Latest Analysis on United Therapeutics

United Therapeutics Profile (Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Featured Stories Five stocks we like better than United Therapeutics Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against? Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Canada Pension Plan Investment Board bought a new position in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 6,200 shares of the biotechnology company’s stock, valued at approximately $3,359,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in UTHR. Arjuna Capital boosted its position in shares of United Therapeutics by 2.8% in the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after purchasing an additional 18 shares during the period. Sage Rhino Capital LLC raised its position in shares of United Therapeutics by 5.1% during the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after purchasing an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC lifted its stake in shares of United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after buying an additional 24 shares in the last quarter. Meeder Advisory Services Inc. lifted its stake in shares of United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after buying an additional 26 shares in the last quarter. Finally, Independent Advisor Alliance boosted its holdings in United Therapeutics by 3.3% in the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after buying an additional 27 shares during the period. Institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics In related news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $547.61, for a total value of $5,202,295.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,185,323.93. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $10,311,581.28. This represents a 34.63% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 404,575 shares of company stock valued at $216,652,640. 8.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades UTHR has been the subject of a number of analyst reports. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday. Morgan Stanley set a $515.00 price objective on United Therapeutics in a research note on Thursday, August 6th. Bank of America cut their target price on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Finally, Royal Bank Of Canada lowered their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $646.00. Get Our Latest Research Report on UTHR

United Therapeutics Stock Performance NASDAQ UTHR opened at $515.46 on Monday. The stock has a 50 day moving average price of $530.46 and a 200-day moving average price of $539.16. United Therapeutics Corporation has a one year low of $303.08 and a one year high of $609.35. The company has a market capitalization of $22.11 billion, a P/E ratio of 18.44, a P/E/G ratio of 1.75 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same period last year, the company posted $6.41 EPS. The business’s revenue was down 1.9% on a year-over-year basis. As a group, equities analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

(Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

See Also Five stocks we like better than United Therapeutics Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally Rubrik’s AI Security Bet Could Power the Next Leg Higher Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four oral presentations and four poster presentations will be

Allworth Financial LP acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 1,167 shares of the biotechnology company’s stock, valued at approximately $632,000.

Other institutional investors also recently modified their holdings of the company. Greenspring Advisors LLC bought a new position in United Therapeutics during the second quarter worth about $223,000. B. Metzler seel. Sohn & Co. AG bought a new position in United Therapeutics during the 2nd quarter worth $595,000. Fairtree Asset Management Pty Ltd acquired a new position in United Therapeutics in the 2nd quarter valued at $1,071,000. Advisors Capital Management LLC acquired a new stake in shares of United Therapeutics during the 2nd quarter worth $457,000. Finally, Vise Technologies Inc. bought a new position in shares of United Therapeutics in the second quarter worth $899,000. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth A number of research analysts recently commented on the company. Weiss Ratings raised United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a report on Thursday, August 6th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, JPMorgan Chase & Co. raised their target price on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

View Our Latest Stock Analysis on United Therapeutics Insiders Place Their Bets In related news, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $523.14, for a total transaction of $4,342,062.00. Following the sale, the executive vice president owned 45,172 shares in the company, valued at $23,631,280.08. This represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $526.96, for a total value of $5,006,120.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $170,968,483.28. This trade represents a 2.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 442,575 shares of company stock worth $239,326,330. Insiders own 8.60% of the company’s stock.

United Therapeutics Price Performance NASDAQ:UTHR opened at $513.12 on Monday. United Therapeutics Corporation has a one year low of $302.19 and a one year high of $609.35. The company has a market cap of $22.01 billion, a PE ratio of 18.36, a P/E/G ratio of 1.74 and a beta of 0.59. The firm’s 50 day simple moving average is $533.08 and its 200 day simple moving average is $537.80.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same period last year, the company earned $6.41 EPS. United Therapeutics’s revenue for the quarter was down 1.9% compared to the same quarter last year. Equities research analysts expect that United Therapeutics Corporation will post 26.33 EPS for the current year.

United Therapeutics Company Profile (Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

See Also Five stocks we like better than United Therapeutics VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways United Therapeutics enrolled 754 PPF patients in the 52-week TETON-PPF Phase III study.The study's primary endpoint is the change in absolute FVC from baseline through week 52.Positive results could support an FDA filing to add PPF to Tyvaso's labeled indications. United Therapeutics (UTHR - Free Report) announced completing enrollment in the phase III TETON-PPF study evaluating Tyvaso (treprostinil) inhalation solution for the treatment of progressive pulmonary fibrosis (PPF). The global registrational study is designed to assess the safety and efficacy of nebulized Tyvaso in this patient population over 52 weeks. Per UTHR, PPF is a progressive form of interstitial lung disease (ILD) marked by worsening lung function and fibrosis, with approximately 200,000 patients estimated to be affected in the United States.

United Therapeutics’ Tyvaso is already approved for two indications. It is indicated to improve exercise ability in patients with pulmonary arterial hypertension (PAH; WHO Group 1) and in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3). However, its use in PPF remains investigational, and the FDA has not approved nebulized Tyvaso for this indication.

UTHR’s Phase III PPF Study Design in DetailUnited Therapeutics’ phase III TETON-PPF placebo-controlled study has enrolled 754 PPF patients who were randomly assigned in a 1:1 ratio to receive either nebulized Tyvaso or placebo. Treatment began at three breaths four times daily and was gradually increased, as tolerated, toward a target of 12 breaths four times daily. The treatment period will run for 52 weeks, with patients who complete the final study visit potentially eligible for an open-label extension.

Year to date, shares of United Therapeutics have gained 4.3% against the industry’s 1.1% decline.

Image Source: Zacks Investment Research

The primary endpoint is the change in absolute forced vital capacity (FVC) from baseline through week 52, which is intended to measure the treatment’s effect on lung function. Secondary endpoints include time to first clinical worsening, time to first acute exacerbation of ILD, overall survival at week 52, change in percent predicted FVC, change in the King’s Brief Interstitial Lung Disease questionnaire score and change in diffusing capacity of the lungs for carbon monoxide.

The study is also collecting data on N-terminal pro-brain natriuretic peptide levels and supplemental oxygen use, while safety assessments cover adverse events, laboratory measures, vital signs and electrocardiograms.

UTHR’s Next StepsHaving completed enrollment in the phase III study evaluating Tyvaso, United Therapeutics expects to report top-line results in the second half of 2027. The readout will be an important milestone for UTHR, as positive results could expand access to a potential new treatment option for patients with PPF, who currently have limited therapies available and face progressive loss of lung function, poorer quality of life and increased mortality.

Subject to the success of the TETON-PPF study, United Therapeutics plans to use the data to support a supplemental new drug application (sNDA) with the FDA to add PPF to the labeled indications for nebulized Tyvaso.

Separately, UTHR is already seeking priority review for an sNDA submitted to the FDA in June 2026 to add idiopathic pulmonary fibrosis to the labeled indications for nebulized Tyvaso, based on data from the TETON-1 and TETON-2 studies.

Under the FDA’s Priority Review pathway, the agency aims to take action on an eligible marketing application within six months compared with 10 months under standard review. Priority Review is generally granted to applications for drugs that treat serious conditions and, if approved, would provide a significant improvement in the safety or effectiveness of treatment, diagnosis or prevention.

UTHR’s Zacks Rank & Stocks to ConsiderUnited Therapeutics currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Amneal Pharmaceuticals (AMRX - Free Report) , Repligen (RGEN - Free Report) and AC Immune (ACIU - Free Report) . AMRX and RGEN currently sport a Zacks Rank #1 (Strong Buy) each, while ACIU carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, earnings estimates for Amneal Pharmaceuticals have increased from $1.00 to $1.02 for 2026. Over the same period, earnings estimates increased from $1.12 to $1.21 for 2027. AMRX shares have risen 46.1% year to date.

Amneal Pharmaceuticals beat earnings in each of the trailing four quarters, delivering an average surprise of 32.82%.

Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.61. RGEN shares have gained 3.2% year to date.

Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.

Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have plunged 19.4% year to date.

AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.

Posted by Defense World Staff on Aug 8th, 2026

Atwood & Palmer Inc. cut its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 1.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 61,479 shares of the biotechnology company’s stock after selling 957 shares during the quarter. United Therapeutics makes up approximately 1.8% of Atwood & Palmer Inc.’s portfolio, making the stock its 23rd biggest position. Atwood & Palmer Inc. owned 0.14% of United Therapeutics worth $33,311,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Avoro Capital Advisors LLC lifted its stake in shares of United Therapeutics by 17.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after purchasing an additional 383,838 shares during the period. Wellington Management Group LLP grew its position in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares during the period. AQR Capital Management LLC increased its stake in shares of United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock valued at $624,508,000 after acquiring an additional 295,221 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after acquiring an additional 70,829 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of United Therapeutics during the 4th quarter valued at $293,418,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting United Therapeutics Here are the key news stories impacting United Therapeutics this week:

Positive Sentiment: Quarterly earnings exceeded expectations. United Therapeutics reported second-quarter EPS of $7.27, above the roughly $6.86 consensus and up from $6.41 a year earlier. Strong profitability, including a net margin above 40%, provides a favorable fundamental backdrop. United Therapeutics Q2 Earnings Beat Estimates Positive Sentiment: Pipeline milestones are offsetting near-term product concerns. Investors are focusing on progress for ralinepag, including its Phase 3 milestone and regulatory applications. The program could provide a new growth driver and reduce reliance on Tyvaso amid competitive pressures. EPS Strength and Ralinepag’s Phase 3 Milestone Positive Sentiment: Analyst sentiment remains favorable. H.C. Wainwright reiterated a Buy rating with a $660 price target. RBC maintained an Outperform rating and set a $677 target, despite reducing its previous target from $704. These targets indicate continued confidence in United Therapeutics’ longer-term prospects. Buy Rating Reiterated on United Therapeutics Neutral Sentiment: Revenue fell short of estimates. Second-quarter revenue was $783.3 million, below the $804.65 million consensus and down 1.9% year over year. The revenue miss highlights near-term pressure even as earnings and pipeline updates were encouraging. United Therapeutics Q2 Earnings Results Negative Sentiment: Senior executives sold sizable positions. CEO Martine Rothblatt sold 9,500 shares for approximately $4.9 million, while EVP Paul Mahon sold 8,300 shares for about $4.3 million. The transactions may reflect personal or scheduled sales, but the reductions in insider ownership could weigh on investor sentiment. United Therapeutics Insider Selling Analysts Set New Price Targets UTHR has been the subject of a number of research reports. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Bank of America cut their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Royal Bank Of Canada reduced their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Morgan Stanley set a $515.00 price target on United Therapeutics in a report on Thursday. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $646.00.

Get Our Latest Analysis on UTHR

United Therapeutics Stock Performance UTHR stock opened at $538.84 on Friday. The company has a market capitalization of $23.11 billion, a PE ratio of 19.28, a price-to-earnings-growth ratio of 1.81 and a beta of 0.59. United Therapeutics Corporation has a one year low of $292.34 and a one year high of $609.35. The company’s 50 day moving average price is $539.43 and its two-hundred day moving average price is $534.22.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $6.41 EPS. On average, research analysts predict that United Therapeutics Corporation will post 26.18 EPS for the current year.

Insider Activity In other news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $564.11, for a total value of $5,641,100.00. Following the completion of the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $10,648,140.36. The trade was a 34.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 482,833 shares of company stock worth $265,555,592 over the last quarter. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Profile (Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Further Reading Five stocks we like better than United Therapeutics Datadog’s Drop Says More About Expectations Than Earnings D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus Solventum Nears Inflection Point As It Begins to Unlock Value Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEComparing Agilent Technologies (NYSE:A) & Many Bright Ideas Technologies (OTCMKTS:MBGNF)

NEXT HEADLINE »Assenagon Asset Management S.A. Cuts Stock Holdings in Axsome Therapeutics, Inc. $AXSM

These 3 Stocks Lowered Their Share Counts Drastically in Q1United Therapeutics NASDAQ: UTHR reported second-quarter 2026 revenue of approximately $783 million, essentially flat from the first quarter, as competitive pressure affected sales of its nebulized TYVASO therapy. Company executives said they expect stronger performance in the second half of the year but did not reaffirm or update previous 2026 revenue-growth expectations.

TYVASO revenue totaled $453 million during the quarter. President and Chief Operating Officer Michael Benkowitz said nebulized TYVASO faced increasing competition in the inhaled prostacyclin category, while TYVASO DPI continued to grow. He said the company exited the quarter with record levels of patient starts, referrals, total patients and commercial patients for the DPI formulation.

Get United Therapeutics alerts:

The Top 3 Stock Picks at the World’s Greatest Hedge Fund“We exited the second quarter with considerably more momentum than the reported revenue line alone would suggest,” Benkowitz said. United Therapeutics expects second-half 2026 performance to exceed first-half results, supported by expanded commercial coverage and patient-demand metrics.

Commercial Expansion Targets PAH and Pulmonary Fibrosis United Therapeutics roughly doubled its sales force and deployed the expanded team in early July, according to Benkowitz. The representatives are currently promoting approved therapies in pulmonary arterial hypertension, or PAH, and pulmonary hypertension associated with interstitial lung disease, or PH-ILD.

Liquidia: Court victory the awakening of an industry giant?The larger field organization is intended to support potential future launches in idiopathic pulmonary fibrosis, or IPF, and PAH. Benkowitz said the IPF patient population is more concentrated in community settings than the company’s current customer base, requiring broader outreach beyond academic medical centers.

Management said the company still sees a path to its previously discussed $4 billion annualized revenue run rate by the end of 2027, although Benkowitz said that path has narrowed. He added that anticipated contributions from potential IPF and ralinepag launches could help the company reach or exceed that level.

United Therapeutics expects second-half 2026 revenue performance to be stronger than the first half. The company did not provide updated 2026 revenue guidance or confirm analysts’ specific TYVASO revenue estimates. Management said TYVASO DPI demand indicators, including starts and referrals, reached record levels exiting the quarter. Regulatory Filings Advance Respiratory Pipeline Chairperson and Chief Executive Officer Martine Rothblatt said the company submitted two major regulatory applications following positive clinical results: a supplemental new drug application, or sNDA, for nebulized TYVASO in IPF and a new drug application, or NDA, for ralinepag in PAH.

Rothblatt characterized the TETON-1 IPF results as exceeding the TETON-2 findings reported last September. She also cited results from the ADVANCE OUTCOMES study of ralinepag, which management believes support the oral therapy’s potential in PAH.

Leigh Peterson, executive vice president of product development and xenotransplantation, said the IPF sNDA was submitted in late June. The company expects to learn shortly whether the FDA will grant priority review. A priority review would carry a six-month review period, compared with 10 months under a standard review, Peterson said.

The company expects potential approvals in 2027 for nebulized TYVASO in IPF, ralinepag in PAH, and its treprostinil small-molecule inhalation device, or SMI, in PAH and PH-ILD. United Therapeutics also plans to file an investigational new drug application for ralinepag DPI and an NDA for treprostinil SMI later this year.

Benkowitz said management views ralinepag as a potential once-daily oral prostacyclin option and a multibillion-dollar opportunity. He said physicians’ initial feedback on the ADVANCE OUTCOMES data has been positive. The company also expects SMI to offer a differentiated method of administering inhaled therapies, potentially including tolerability benefits.

IPF Launch Would Initially Use Nebulized TYVASO If TYVASO receives approval in IPF next year, the initial launch would involve the nebulized formulation only. Benkowitz said United Therapeutics remains in discussions with the FDA regarding the data needed to support IPF indications for TYVASO DPI and SMI.

Peterson said the company has proposed bridging strategies for both DPI and SMI and is seeking FDA feedback. Management did not specify whether additional efficacy studies would be required.

In discussions with physicians following the TETON results, Benkowitz said clinicians have expressed interest in using TYVASO alongside other IPF medicines. He said providers expect IPF treatment to move toward a polytherapy approach, similar to treatment patterns in PAH, although sequencing would depend on individual patients.

United Therapeutics also said enrollment in its TETON PPF trial is nearly complete and ahead of schedule. The company expects to disclose baseline characteristics of enrolled progressive pulmonary fibrosis patients at future conferences and anticipates a Phase 3 readout in the second half of 2027.

Xenotransplantation and Organ Programs Progress Beyond its pulmonary portfolio, United Therapeutics continues to advance organ-transplantation programs. Rothblatt said the UKidney EXPAND study’s initial six-patient cohort is expected to be completed later this year, while the company anticipates initiating the UThymoKidney EXTEND registration-enabling study. Following FDA clearance, the company is also preparing to begin the EXPRESS-UHeart study.

The company expects to complete construction by year-end on two additional commercial-scale designated pathogen-free facilities in Minnesota and Texas. Rothblatt also noted the recent acquisition of Thymmune Therapeutics, which added a thymus-based regenerative medicine platform to United Therapeutics’ organ-alternative strategy.

About United Therapeutics (NASDAQ:UTHR)United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in United Therapeutics Right Now?Before you consider United Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.

While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

United Therapeutics (UTHR - Free Report) came out with quarterly earnings of $7.27 per share, beating the Zacks Consensus Estimate of $6.82 per share. This compares to earnings of $6.41 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +6.60%. A quarter ago, it was expected that this drugmaker would post earnings of $6.73 per share when it actually produced earnings of $5.82, delivering a surprise of -13.52%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

United Therapeutics, which belongs to the Zacks Medical - Drugs industry, posted revenues of $783.3 million for the quarter ended June 2026, missing the Zacks Consensus Estimate by 2.51%. This compares to year-ago revenues of $798.6 million. The company has not been able to beat consensus revenue estimates over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

United Therapeutics shares have added about 6.5% since the beginning of the year versus the S&P 500's gain of 13%.

What's Next for United Therapeutics?While United Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for United Therapeutics was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $7.03 on $819.4 million in revenues for the coming quarter and $26.65 on $3.23 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

MediWound (MDWD - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on August 13.

This developer of treatments for burns and hard-to-heal wounds is expected to post quarterly loss of $0.76 per share in its upcoming report, which represents a year-over-year change of +38.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

MediWound's revenues are expected to be $2.59 million, down 54.7% from the year-ago quarter.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2026. Total revenues in the second quarter of 2026 decreased by two percent year-over-year to $783.3 million, compared to $798.6 million in the second quarter of 2025. “We just submitted what we believe are two of the most important NDAs in rare pulmonary disease history: ralinepag t.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that The Lancet has published full results of its ADVANCE OUTCOMES study, available here. Ralinepag has not been approved for use in any indication by the FDA and remains investigational for PAH. Ralinepag reduced the risk of a clinical worsening event by 55% compared with placebo in patients with PAH (hazard ratio 0.45, 95% CI [0.33-0.

Key Takeaways Liquidia's Yutrepia launch has driven strong sales, adoption and three straight profitable quarters. LQDA projects far faster 2026 revenue and EPS growth, backed by rising earnings estimates.United Therapeutics counters with a broad PAH portfolio and late-stage ralinepag pipeline. Liquidia Corporation (LQDA - Free Report) is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

United Therapeutics (UTHR - Free Report) boasts six FDA-approved therapies that treat PAH, PH-ILD, and neuroblastoma, a rare pediatric cancer, in its portfolio.

Liquidia and United Therapeutics are locked in a fierce battle in the PAH market, with Liquidia's Yutrepia emerging as a challenger to United Therapeutics' blockbuster Tyvaso franchise. Their competition extends beyond commercial sales to patent disputes and a race to capture a larger share of the inhaled treprostinil market.

Given this backdrop, selecting one stock over the other can be difficult. We therefore evaluate their fundamentals, growth prospects, challenges and valuation metrics to help make an informed decision.

The Case for LQDALiquidia currently markets Yutrepia (treprostinil) inhalation powder, approved by the FDA in May 2025 and launched the following month commercially.

The company also generates revenues through a profit-sharing agreement with Sandoz for the promotion of its generic treprostinil injection in the United States.

Yutrepia is an inhaled dry-powder formulation of treprostinil developed using Liquidia's proprietary PRINT particle engineering technology. The platform is designed to enhance deep lung drug delivery, simplify administration through a low-effort dry-powder inhaler and enable higher dose levels than currently marketed inhaled treprostinil therapies.

The company supports commercialization through a specialized sales force focused on physicians treating PAH and PH-ILD, as well as stakeholders involved in reimbursement and drug distribution.

Since its launch in June 2025, Yutrepia has emerged as a strong growth driver, generating approximately $130 million in first-quarter 2026 sales. The therapy has demonstrated robust adoption, with more than 4,500 unique prescriptions, around 3,750 patients initiating treatment, and nearly 1,000 physicians prescribing the drug.

Its rapid uptake helped Liquidia post its third consecutive profitable quarter, highlighting Yutrepia's growing commercial success.

Beyond its commercial portfolio, Liquidia is advancing a pipeline of therapies for pulmonary vascular diseases. Its lead pipeline candidate, L606, is an investigational liposomal formulation of treprostinil administered twice daily via a next-generation nebulizer. L606 is being evaluated in an open-label study for PAH and PH-ILD, while a global pivotal placebo-controlled trial is underway in PH-ILD.

Liquidia also plans to expand Yutrepia into additional indications, including pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF) and Raynaud's phenomenon associated with systemic sclerosis.

The Case for UTHRUnited Therapeutics markets a broad PAH portfolio led by Tyvaso DPI, a dry-powder inhaled formulation of the prostacyclin analogue treprostinil, which was approved by FDA in May 2022 to improve exercise ability in patients with PAH and PH-ILD.

Its portfolio includes nebulized Tyvaso, a nebulized liquid inhaled formulation of treprostinil, approved by the FDA to improve exercise ability in patients with PAH and PH-ILD.

The company also markets Remodulin, a continuously infused treprostinil therapy for PAH administered subcutaneously or intravenously, supported by the user-friendly RemunityPRO infusion pump. Its PAH portfolio further includes Orenitram, an oral extended-release treprostinil tablet, and Adcirca (tadalafil), an oral PDE-5 inhibitor licensed from Eli Lilly through the end of 2026.

Sales of Tyvaso products continue to grow, driven by higher volumes and continued growth in commercialization utilization. Moreover, Orenitram offers a convenient oral treatment option that avoids the challenges associated with continuous infusion therapies, such as Remodulin, and inhaled therapies requiring multiple daily administrations.

The company remains focused on developing additional therapies for PAH and pulmonary fibrosis (PF).

Ralinepag, an investigational, highly selective and potent prostacyclin (IP) receptor, is one of United Therapeutics' most promising late-stage pipeline assets. The candidate is being developed in two formulations — an oral version and a DPI version (RAL-DPI).

Based on positive data from the pivotal phase III ADVANCE OUTCOMES study, United Therapeutics intends to submit a new drug application for ralinepag (to treat PAH) to the FDA by the second half of 2026.

If approved, oral ralinepag could strengthen United Therapeutics’ leadership in PAH and potentially offset future competitive pressure on older products.

Beyond the oral formulation, United Therapeutics is also developing inhaled dry-powder versions of ralinepag, RAL-DPI, in collaboration with MannKind Corporation. While initially targeting PAH, management sees opportunities for RAL-DPI in PH-ILD, IPF and PPF. Together, the oral and inhaled formulations position ralinepag as a potential cornerstone of United Therapeutics' future growth strategy.

Outside its PAH franchise, the company markets Unituxin for the treatment of high-risk neuroblastoma.

UTHR strengthened its long-term regenerative medicine strategy by acquiring preclinical stage biotech Thymmune Therapeutics for $140 million upfront, with up to $160 million in milestone payments. The deal adds THY-100, a stem cell-derived thymic cell therapy being developed for congenital athymia, and a platform with potential applications in organ transplantation, autoimmune diseases and immune deficiencies.  The acquisition broadens United Therapeutics' pipeline beyond PAH.

A Look at Estimates: LQDA versus UTHRThe Zacks Consensus Estimate for LQDA’s 2026 sales implies a year-over-year increase of 315.77%, while that for earnings per share (EPS) suggests a year-over-year improvement of 477.5%. The Zacks Consensus Estimate for 2026 EPS has moved north to $3.02 from $2.97 and that for 2027 EPS has increased to $4.92 from $4.81 in the past 60 days.

LQDA’s Estimate Movement
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for UTHR’s 2026 sales implies a year-over-year increase of 1.46%, while that for EPS suggests a year-over-year decline of 4.41%.  EPS estimates for 2026 have moved south to $26.63 in the past 60 days but those for 2026 have moved north to $31.66 from $31.09 during the said time frame.

UTHR’s Estimate Movement
Image Source: Zacks Investment Research

Price Performance and Valuation of LQDA and UTHRFrom a price-performance perspective, LQDA has fetched better returns than UTHR so far in the year. Shares of LQDA have surged 158.2%, while those of UTHR have gained 8.7%. The industry has gained 1.4% in the said period.

Image Source: Zacks Investment Research

From a valuation standpoint, LQDA is more expensive than UTHR. LQDA’s shares currently trade at 8.74X forward sales, higher than 6.50X for UTHR.

Image Source: Zacks Investment Research

Which Stock Is a Better Pick for Now?LQDA currently sports a Zacks Rank #1 (Strong Buy), while UTHR carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Although United Therapeutics remains the established leader in PAH with a diversified portfolio, a robust late-stage pipeline and expansion into regenerative medicine, much of its growth appears incremental.

In contrast, Liquidia is in the early stages of a rapid commercial expansion, driven by the impressive launch of Yutrepia, expanding label opportunities and a promising pipeline. The company's superior revenue and earnings growth outlook, upward estimate revisions, stronger year-to-date share price performance and better Zacks Rank outweigh its premium valuation.

While UTHR remains a solid long-term holding, Liquidia offers the more compelling growth story and greater upside potential at current levels, making LQDA the better pick for investors seeking higher returns.

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors appointed Victor Dzau, M.D.,

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2026 financial results in a press release that will be issued on Wednesday, August 5, 2026, at approximately 6:30 a.m. Eastern Time.United Therapeutics will host a public webcast on Wednesday, August 5, 2026, at 9:00 a.m. Eastern Time that will be accessible at https://ir.unither.com/events-and-presentations. A rebroadcast of th.

Key Takeaways UTHR reported positive phase III results for Tyvaso in IPF, supporting a planned FDA supplemental filing.UTHR plans an FDA filing for ralinepag after phase III success & targets $4B annual revenue run rate by 2027.UTHR is advancing organ manufacturing while facing growing competition for its core PAH therapies. Shares of United Therapeutics (UTHR - Free Report) have gained 14% year to date against the industry’s 0.8% decline, driven by major clinical breakthroughs and improved long-term growth visibility that have significantly strengthened investor confidence.

Image Source: Zacks Investment Research

UTHR’s Meaningful Pipeline Expansion Encourages InvestorsInvestor sentiment has been boosted by encouraging progress across United Therapeutics' pipeline.

The company is expanding nebulized Tyvaso beyond its approved pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) indications into larger pulmonary fibrosis markets such as idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The company's IPF development program consists of two pivotal phase III studies, TETON-1 and TETON-2. The studies share a similar design, differing primarily in their geographic scope. TETON-1 was conducted at sites across the United States and Canada, while TETON-2 enrolled patients at sites outside these countries.

In March 2026, the company announced positive results from the late-stage TETON-1 study, which achieved its primary endpoint by demonstrating a statistically significant improvement in lung function for patients with IPF. The magnitude of benefit observed in TETON-1 exceeded the already strong outcomes previously reported in TETON-2, representing a significant advancement for patients with IPF.

Positive phase III data from both the TETON-1 and TETON-2 studies support a planned FDA supplemental application for Tyvaso in IPF. Management believes the IPF opportunity alone could eventually surpass Tyvaso's current PAH revenues. It is also enrolling patients in the phase III TETON PPF study evaluating the drug in patients with PPF.

The company's late-stage PAH candidate ralinepag delivered positive phase III data from the ADVANCE OUTCOMES study in March. The study met its primary and secondary endpoints. UTHR intends to submit a new drug application for ralinepag to the FDA in the second half of 2026. 

The company is developing an inhaled dry-powder version of ralinepag (RAL-DPI) in collaboration with MannKind Corporation. While initially targeting PAH, management sees potential opportunities for RAL-DPI in PH-ILD, IPF and PPF.

Together, Tyvaso's label expansion and the ralinepag franchise are expected to drive long-term growth, supporting the company's goal of increasing its annual revenue run rate from $3 billion to $4 billion by the end of 2027 and boosting investor sentiment.

Organ Manufacturing Business on MoveUnited Therapeutics continues to strengthen its long-term growth outlook through steady progress in its organ manufacturing platform, which spans hearts, kidneys, livers and lungs. The company is advancing multiple technologies, including xenotransplantation, regenerative medicine, bioengineered organs, 3D bioprinting and ex-vivo lung perfusion (EVLP) to address the global shortage of donor organs.

Its xenotransplantation portfolio includes development-stage candidates UKidney, UHeart and UThymoKidney. The FDA cleared the investigational new drug application for the phase I EXPRESS study evaluating UHeart in May. United Therapeutics received FDA premarket approval for LungFX, the first EVLP device for assessing donor lungs outside the body, with a commercial launch planned for 2027.

Earlier this month, the acquisition of Thymmune Therapeutics expanded the company's regenerative medicine portfolio with the preclinical thymic cell therapy THY-100, strengthening its long-term strategy to improve organ transplantation and immune restoration.

UTHR Faces Competitive PressureUnited Therapeutics generates most of its revenues from its treprostinil-based PAH therapies, including Tyvaso, Orenitram, Adcirca and Remodulin. The company markets two versions of Tyvaso: Tyvaso dry powder inhalation (DPI) and nebulized Tyvaso. The drug remains the company's biggest growth driver, with the more convenient Tyvaso DPI continuing to gain traction and posting 9% year-over-year sales growth in the first quarter of 2026.

A key concern for United Therapeutics is the increasing competitive pressure on its core PAH franchise. While Tyvaso DPI continues to grow, sales of nebulized Tyvaso have been declining due to market erosion following the loss of exclusivity in May 2025 and the FDA approval of Liquidia Corporation’s (LQDA - Free Report) Yutrepia, the first inhaled dry-powder competitor for PAH and PH-ILD. Yutrepia's rapid market adoption, with 44% sequential sales growth in the first quarter of 2026, underscores the growing competitive threat to Tyvaso products.

UTHR’s heavy reliance on the PAH market remains a risk as its established therapies face rising competition from generics and newer treatments. With limited diversification beyond PAH, United Therapeutics' long-term growth depends largely on the successful development and commercialization of its pipeline, making any clinical, regulatory or commercialization setbacks a potential headwind for the stock.

UTHR's Zacks Rank & Stocks to ConsiderUnited Therapeutics currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Neurocrine Biosciences (NBIX - Free Report) and Amarin Corporation (AMRN - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Neurocrine Biosciences’ 2026 earnings per share have risen from $9.15 to $9.47. Over the same period, EPS estimates for 2027 have risen from $10.23 to $10.79. NBIX shares have lost 25.6% year to date.

Neurocrine Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 9.08%.

Over the past 60 days, loss per share estimates for Amarin Corporation have narrowed from $15.20 to 65 cents for 2026. Over the same period, estimates for loss per share have also narrowed from $13.00 to 51 cents for 2027. AMRN shares have risen 8.5% year to date.

Amarin Corporation’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 50.02%.

HomeStock IdeasLong IdeasHealthcare 

SummaryRegencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant treatment gaps. I reiterate a Strong Sell on RGC, citing reliance on cost-cutting, high dilution risk, and a DOJ trading investigation overhang. RGC's valuation is unsustainable without externally validated clinical and commercial progress; shares have collapsed ~73% after a prior speculative surge. I contrast RGC’s speculative profile with United Therapeutics (UTHR), which offers proven commercial products, cash flow, and profitability. UTHR earns a Buy rating as Tyvaso expansion, ralinepag progress, and transplant investments support a multi-year earnings growth outlook. Tom Werner/DigitalVision via Getty Images

Thesis Regencell Bioscience Holdings Limited (RGC) is a Hong Kong bioscience company conducting research and development in TCM (Traditional Chinese Medicine) and its applications in neurocognitive degeneration and disorders. Their primary area

3.02K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of UTHR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I do not own or trade RGC Regencell Bioscience Holdings.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases.

The thymus is a critical organ for the development and proper function of key parts of the immune system, including training T-cells, which are essential for fighting infections and other diseases. Thymmune has a proprietary process for converting human-induced pluripotent stem cells (iPSC) into thymic cells, which — once inside the body — mature into cell types that can restore healthy T-cell function.

Thymmune’s lead candidate, THY-100, is in preclinical development for congenital athymia, an ultra-rare and life-threatening condition in which infants are born without a functional thymus. Animal studies have shown that treatment with THY-100 results in the in vivo formation of a neo-thymus that is capable of facilitating T-cell development. The clinical proof of concept and further development of THY-100 has the potential to broaden thymic regenerative medicine approaches for transplant tolerance, serious immune-mediated diseases, and enhanced longevity for older adults with diminished T-cell function.

“Thymmune’s platform complements United Therapeutics’ broader mission to expand the supply of transplantable organs, building on our UThymoKidney™ clinical development program and our growing strength in immunomodulatory therapeutics,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. “By restoring or modulating T-cell receptor diversity, Thymmune’s technology could make fundamental contributions to human health care and potentially resolve the root causes of dozens of life-threatening diseases.”

“Thymmune was founded to harness the biology of the thymus to restore immune function for patients with serious immune-mediated diseases,” said Stan Wang, M.D., Ph.D., Chief Executive Officer and Founder of Thymmune Therapeutics. “United Therapeutics shares our conviction that regenerative medicine can transform the lives of patients, and we believe its leadership in organ alternatives and cell-based technologies makes it the ideal partner to advance our platform toward broad clinical impact.”

Under the terms of the agreement, United Therapeutics acquired Thymmune for $140 million in cash, subject to certain post-closing adjustments, plus potential earn-out payments to former Thymmune equityholders of up to $160 million based upon the achievement of certain clinical and regulatory milestones by the end of 2031.

About United Therapeutics

Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build. Visit us at www.unither.com and follow us on LinkedIn, Facebook, and Instagram.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding our plans to develop THY-100 and other products based on Thymmune’s technology, including the potential to broaden thymic regenerative medicine approaches for transplant tolerance, serious immune-mediated diseases, and enhanced longevity for older adults with diminished T-cell function, the potential for Thymmune’s technology to support our organ manufacturing programs, the potential for Thymmune’s technology to make fundamental contributions to human health care and potentially resolve the root causes of dozens of life-threatening diseases, the potential earn-out payments to the former Thymmune stockholders, our goals of expanding the supply of transplantable organs, developing practical technologies that can save lives, creating long-term shareholder value, and operating with sustainable practices. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of July 2, 2026, and assume no obligation to update or revise the information contained in this press release whether because of new information, future events, or any other reason.

UTHYMOKIDNEY is a trademark of United Therapeutics Corporation.

The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPI United Therapeutics plans to be the primary manufacturer of ralinepag DPI MannKind eligible to receive up to $35 million in development milestones plus 10% royalties on net sales DANBURY, Conn.

United Therapeutics Corporation (UTHR) Q1 2026 Earnings Call Transcript

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that 12 new data presentations across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference, May 15-20, in Orlando. “We are thrilled to share additional positive data from the TETON-1 study in IPF and the ADVANCE OUTCOMES study in PAH, our pivotal studies that achieve.

/PRNewswire/ -- Varda Space Industries today announced a collaboration with United Therapeutics Corporation (Nasdaq: UTHR) to explore the use of microgravity

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company's Investigational New Drug application to proceed with a clinical study of its investigational UHeart™ derived from a pig with 10 gene edits. The study, known as EXPRESS, will enroll an initial cohort of up to two participants. United Therapeutics.

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that full results of its ADVANCE OUTCOMES study are being present